Bristol-Myers Squibb Company

New York Stock Exchange
Back to all articles
Bullish +75

Bristol-Myers Squibb: The CAR-T Giant The Market Is Undervaluing

AI-generated analysis

📉 Bristol-Myers Squibb (BMY) stock currently trades at a low 9.4x forward P/E ratio, driven primarily by market concerns over an upcoming patent cliff.

💊 The company is considered well-equipped with a robust pipeline and significant CAR-T therapy optionality to navigate potential challenges.

📈 Investors could see 15-20% base case upside if the stock re-rates toward a 10x-11x forward P/E multiple based on new catalysts.

💹 BMY offers an attractive 4.3% dividend yield, adding to its potential as an undervalued investment target.

🚀 Key 2026 drug catalysts include Milvexian, Iberdomide, Cobenfy, and Sotyktu, which are expected to drive growth in specific indications.

🔬 The company's advanced CAR-T program features zola-cel targeting autoimmune diseases, representing a long-term growth avenue not yet fully priced into the valuation.

📝 The article author, Joseph "Kade" Minton, is an engineering physics background investor who focuses on speculative growth stocks in biotech and tech sectors.

🤖 The author posits that the biotech sector is entering a golden era with breakthroughs in cancer, Alzheimer's, and autoimmune disorder treatments.

⚠️ The analysis highlights that while patent expiration fears are prevalent, the market has significantly underpriced BMY's potential value.

🔍 The article serves as an investment thesis suggesting BMY is undervalued despite traditional risks associated with biotech patents expiring.

Bullish Signals
  • Bristol-Myers Squibb (BMY) trades at a discounted 9.4x forward P/E, presenting a compelling entry point with an estimated 15-20% base case upside.
  • The company offers a generous 4.3% dividend yield, providing downside protection and income potential for investors.
  • A strong pipeline of catalysts including Milvexian, Iberdomide, Cobenfy, and Sotyktu is positioned to drive a potential valuation rerating to 10x-11x forward P/E.
  • The advanced CAR-T program, specifically zola-cel for autoimmune diseases, provides long-term optionality that remains largely unpriced into the current stock valuation.
  • Despite fears of a patent cliff, management is well-equipped with a robust pipeline and significant strategic assets to sustain future growth.
Risk Factors
  • Bristol-Myers Squibb faces a 'major patent cliff', with multiple patents expiring within a short timeframe, which is the primary reason the stock trades at a discounted 9.4x forward P/E.
  • The current valuation of 9.4x forward P/E reflects significant market fears regarding revenue decline due to patent expirations.
Full Analysis
Published on May 2, 2026, this article argues that Bristol-Myers Squibb Company (BMY) is currently undervalued by the market despite facing a significant patent cliff in 2026. The stock is trading at a discounted forward price-to-earnings ratio of 9.4x, a valuation driven largely by investor fears regarding expiring patents. However, the author contends that the company is robustly equipped to navigate this challenge with a strong pipeline and substantial CAR-T optionality that remains largely unpriced in the current valuation model. Underlying these risks are compelling fundamentals, including a 15-20% base case upside potential combined with a 4.3% dividend yield. The near-term catalyst stack for BMY in 2026 includes several key compounds: Milvexian, Iberdomide, Cobenfy, and Sotyktu. The article suggests that the success of any one of these assets could trigger a significant rerating of the stock, pushing its forward P/E multiple from current levels to a range of 10x-11x. Beyond these immediate drivers, BMY's advanced CAR-T program, particularly zola-cel targeted for autoimmune indications, is highlighted as a major source of long-term optionality that offers further upside potential beyond the current market consensus. The author of the piece, Joseph "Kade" Minton, identifies himself as an engineering physics and applied mathematics graduate who now works in environmental and industrial compliance. He utilizes quantitative models incorporating concepts such as differential equations and linear algebra, while balancing them with macroeconomic winds and historical regulatory precedent to identify speculative growth stocks he believes are undervalued. His broader thesis posits that the biotech sector is approaching a golden era characterized by revolutionary breakthroughs in treating diseases like cancer, Alzheimer's, and autoimmune disorders, alongside advancements in technology such as fusion energy and solid-state batteries. The author discloses holding beneficial long positions in shares of KYTX, RNAC, CABA, and CRBU, though he states he does not hold a business relationship with any company mentioned in the text except for those specific holdings or through Seeking Alpha. Seeking Alpha's standard disclaimers note that past performance does not guarantee future results and that the article expresses the author's own opinions rather than the views of the platform as an investment advisor. The content explicitly avoids giving recommendations or advice on investment suitability for any particular investor.